Previsioni

Non sono disponibili dati degli analisti per questa azienda.

Notizie Vai al feed delle notizie

Helix Biopharma: EPS for quarter ended 30 April 2026 improved to -0.01 CAD

Helix Biopharma released figures for the quarter ended 30 April 2026 and reported earnings per share of -0.01 CAD. In the same quarter last year, EPS was -0.030 CAD. » Altro su finanzen.net
Helix Biopharma reports improved quarterly EPS of -0.01 CAD

Helix Biopharma released figures for the quarter ended October 31, 2025, and reported earnings per share of -0.01 CAD, compared with -0.030 CAD in the year-ago quarter. No further financial details were provided. » Altro su finanzen.net
Helix unveils aircraft design claiming up to 90% lower fuel use

U.K.-based electric motor specialist Helix released a white paper detailing a hybrid-electric regional aircraft architecture that uses lightweight high-density motors, ducted fans and a compact generator to cut fuel burn dramatically on flights under 250 nautical miles. The design uses electric power for takeoff and landing while recharging batteries in flight, and Helix says it can reduce fuel consumption by as much as 90% (or about 74% versus comparable aircraft) for short routes. The report situates the concept amid growing short-haul market opportunity and notes other firms like JetZero are also pursuing more efficient aircraft designs. » Altro su tech.yahoo.com

Dati finanziari dell'azienda

Nell'ultimo trimestre, Helix BioPharma Co. ha registrato ricavi pari a 0 € e un utile netto di -421,11K €

(EUR)	aprile 2026	YoY
Ricavi	0	-
Utile lordo	-627,17	54,95%
Utile netto	-421,11K	57,41%
EBITDA	-432,41K	56,15%

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	112,62 Mln €
Numero di azioni	76,38 Mln
Massimo/minimo a 52 settimane	1,49 € - 0,52 €
Dividendi	No
Beta	-0,35
Rapporto P/E	-43,86
Rapporto PEG	-0,16
Rapporto P/B	10,04
Rapporto P/S	0,00

Profilo aziendale

Helix BioPharma Corp. ist als Immun-Onkologie-Unternehmen in Kanada tätig. Es entwickelt L-DOS47 für die Behandlung von nicht-kleinzelligem Lungenkrebs und V-DOS47, das auf den vaskulären epithelialen Wachstumsfaktor-Rezeptor 2 abzielt. Helix BioPharma Corp. hat Kooperationsvereinbarungen mit dem Moffitt Cancer Center geschlossen, um die Pharmakodynamik von L-DOS47 zu untersuchen und die Vorteile einer Kombination von L-DOS47 mit Immun-Checkpoint-Inhibitoren zu ermitteln, und mit ProMab Biotechnologies, Inc. zur Entwicklung einer neuartigen Antikörper- und chimären Antigenrezeptor-T-Zell-Therapie zur Behandlung des Multiplen Myeloms sowie Lizenzvereinbarungen mit Xisle Pharma Ventures Trust und National Research of Council Canada. Der Hauptsitz des Unternehmens befindet sich in Richmond Hill, Kanada.